Enzalutamide Superior to Bicalutamide in Castration-resistant Prostate Cancer

Enzalutamide Superior to Bicalutamide in Castration-resistant Prostate Cancer

Survival with enzalutamide, an androgen inhibitor, was superior to bicalutamide in the treatment of men with castration-resistant prostate cancer (CRPC).1 Bicalutamide is currently the most common antiandrogen agent used in the second-line treatment of …

(Visited 3 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.